These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 10962580)

  • 1. Identification of genomic DNA sequences bound by mutant p53 protein (Gly245-->Ser) in vivo.
    Koga H; Deppert W
    Oncogene; 2000 Aug; 19(36):4178-83. PubMed ID: 10962580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53: "gain of function" through perturbation of nuclear structure and function?
    Deppert W; Göhler T; Koga H; Kim E
    J Cell Biochem Suppl; 2000; Suppl 35():115-22. PubMed ID: 11389540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definition of a consensus binding site for p53.
    el-Deiry WS; Kern SE; Pietenpol JA; Kinzler KW; Vogelstein B
    Nat Genet; 1992 Apr; 1(1):45-9. PubMed ID: 1301998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific binding of MAR/SAR DNA-elements by mutant p53.
    Müller BF; Paulsen D; Deppert W
    Oncogene; 1996 May; 12(9):1941-52. PubMed ID: 8649855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific and complex interactions of murine p53 with DNA.
    Weissker SN; Müller BF; Homfeld A; Deppert W
    Oncogene; 1992 Oct; 7(10):1921-32. PubMed ID: 1408133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of protein-DNA association in vivo by chromatin immunoprecipitation.
    Kuras L
    Methods Mol Biol; 2004; 284():147-62. PubMed ID: 15173614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chromatin immunoprecipitation and its preliminary application for gene regulation].
    Zhang Y; Cheng XK; Wu NH; Shen YF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Feb; 26(1):52-5. PubMed ID: 15052775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cysteine residues of the hepatitis B virus onco-protein HBx are not required for its interaction with RNA or with human p53.
    de Moura PR; Rui E; de Almeida Gonçalves K; Kobarg J
    Virus Res; 2005 Mar; 108(1-2):121-31. PubMed ID: 15681062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
    Brazda V; Muller P; Brozkova K; Vojtesek B
    Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Identification of two new p53 target genes through implementation of the modified chromatin immunoprecipitation method and inverse PCR].
    Burgess R; Luniak V; Noskin L; Giliano N
    Mol Biol (Mosk); 2002; 36(6):1035-43. PubMed ID: 12500542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.
    Rippin TM; Bykov VJ; Freund SM; Selivanova G; Wiman KG; Fersht AR
    Oncogene; 2002 Mar; 21(14):2119-29. PubMed ID: 11948395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-antigen interactions with chromatin and p53 during the cell cycle in extracts from xenopus eggs.
    Vassetzky YS; Tchang F; Fanning E; Méchali M
    J Cell Biochem; 1999 Nov; 75(2):288-99. PubMed ID: 10502301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo footprinting and DNA affinity chromatography for analysis of p53 DNA binding ability.
    Molina MP; Cain C; Bargonetti J
    Methods Mol Biol; 2003; 234():151-70. PubMed ID: 12824531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of protein-DNA interactions in vivo by chromatin immunoprecipitation.
    Im H; Grass JA; Johnson KD; Boyer ME; Wu J; Bresnick EH
    Methods Mol Biol; 2004; 284():129-46. PubMed ID: 15173613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The complex interactions of p53 with target DNA: we learn as we go.
    Kim E; Deppert W
    Biochem Cell Biol; 2003 Jun; 81(3):141-50. PubMed ID: 12897847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression.
    Mirza A; Wu Q; Wang L; McClanahan T; Bishop WR; Gheyas F; Ding W; Hutchins B; Hockenberry T; Kirschmeier P; Greene JR; Liu S
    Oncogene; 2003 Jun; 22(23):3645-54. PubMed ID: 12789273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A hidden Markov model for analyzing ChIP-chip experiments on genome tiling arrays and its application to p53 binding sequences.
    Li W; Meyer CA; Liu XS
    Bioinformatics; 2005 Jun; 21 Suppl 1():i274-82. PubMed ID: 15961467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of p53 target database via integration of microarray and global p53 DNA-binding site analysis.
    Liu S; Mirza A; Wang L
    Methods Mol Biol; 2004; 281():33-54. PubMed ID: 15220520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant p53 forms a complex with Sp1 on HIV-LTR DNA.
    Chicas A; Molina P; Bargonetti J
    Biochem Biophys Res Commun; 2000 Dec; 279(2):383-90. PubMed ID: 11118296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.